DE60037394D1 - VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE - Google Patents
VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIEInfo
- Publication number
- DE60037394D1 DE60037394D1 DE60037394T DE60037394T DE60037394D1 DE 60037394 D1 DE60037394 D1 DE 60037394D1 DE 60037394 T DE60037394 T DE 60037394T DE 60037394 T DE60037394 T DE 60037394T DE 60037394 D1 DE60037394 D1 DE 60037394D1
- Authority
- DE
- Germany
- Prior art keywords
- inhibitors
- treatment
- side effects
- cancer therapy
- injuries
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11788199P | 1999-01-29 | 1999-01-29 | |
US117881P | 1999-01-29 | ||
PCT/US2000/002104 WO2000044364A2 (en) | 1999-01-29 | 2000-01-28 | P53 inhibitors and their use for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60037394D1 true DE60037394D1 (de) | 2008-01-24 |
DE60037394T2 DE60037394T2 (de) | 2009-01-02 |
Family
ID=22375329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60037394T Expired - Lifetime DE60037394T2 (de) | 1999-01-29 | 2000-01-28 | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE |
Country Status (11)
Country | Link |
---|---|
US (7) | US6593353B1 (de) |
EP (1) | EP1143943B1 (de) |
JP (2) | JP2002535357A (de) |
AT (1) | ATE380548T1 (de) |
AU (1) | AU3584200A (de) |
CA (1) | CA2360671A1 (de) |
DE (1) | DE60037394T2 (de) |
IL (3) | IL144294A0 (de) |
NZ (1) | NZ513487A (de) |
WO (1) | WO2000044364A2 (de) |
ZA (1) | ZA200105823B (de) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ513487A (en) * | 1999-01-29 | 2003-02-28 | Univ Illinois | The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
EP1303502A2 (de) * | 2000-07-06 | 2003-04-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Tetrahydrobenzothiazol-analoge als neuroprotektive mittel |
WO2002014321A1 (en) * | 2000-08-11 | 2002-02-21 | The Regents Of The University Of California | Use of stat-6 inhibitors as therapeutic agents |
US6696441B1 (en) | 2000-08-11 | 2004-02-24 | The Regents Of The University Of California | Inhibition of p53-induced stress response |
AU2002254342A1 (en) | 2001-03-23 | 2002-10-08 | The Board Of Trustees Of The University Of Illinois | Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same |
US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
WO2004089345A1 (en) * | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals Inc. | Bone targeting of biodegradable drug-containing nanoparticles |
US20040198783A1 (en) * | 2003-04-03 | 2004-10-07 | Semafore Pharmaceuticals Inc. | Targeted bone marrow protection agents |
US7657893B2 (en) * | 2003-04-23 | 2010-02-02 | International Business Machines Corporation | Accounting method and logic for determining per-thread processor resource utilization in a simultaneous multi-threaded (SMT) processor |
US7132421B2 (en) * | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
CN1871341A (zh) * | 2003-08-20 | 2006-11-29 | 悉尼北方和中部海岸区医疗服务系统 | 提高胚胎生存力的方法 |
CA2577196C (en) | 2004-08-23 | 2016-01-12 | Johannes Herkel | Peptide inhibitors for mediating stress responses |
DK1799269T3 (en) * | 2004-09-28 | 2016-10-03 | Quark Pharmaceuticals Inc | Oligoribonucleotides and methods of use thereof for treating alopecia, acute renal failure, and other diseases |
AU2005307772B2 (en) * | 2004-11-16 | 2010-06-10 | Limerick Biopharma, Inc. | Methods and compositions for treating pain |
US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
KR100877824B1 (ko) * | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
US9066976B2 (en) | 2005-11-11 | 2015-06-30 | Korea Research Institute Of Bioscience And Biotechnology | Method for therapeutic angiogenesis |
US20070110756A1 (en) * | 2005-11-14 | 2007-05-17 | Reinberg Danny F | Method for modulating P53 activity via methylation |
US7825099B2 (en) * | 2006-01-20 | 2010-11-02 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
US7910566B2 (en) * | 2006-03-09 | 2011-03-22 | Quark Pharmaceuticals Inc. | Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNA |
BRPI0720546A2 (pt) * | 2006-12-14 | 2015-06-23 | Daiichi Sankyo Co Ltd | Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto |
FR2910895B1 (fr) * | 2006-12-29 | 2010-08-27 | Biopharmed | "derives d'imino-tetrahydrobenzotriazoles ayant des proprietes anti-migratoires de metastases met dependantes" |
CA2939778C (en) * | 2007-01-31 | 2019-01-29 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
CN101730708B (zh) | 2007-03-28 | 2013-09-18 | 哈佛大学校长及研究员协会 | 缝合多肽 |
DK2170403T3 (da) * | 2007-06-27 | 2014-06-16 | Quark Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener |
AU2009310352A1 (en) * | 2008-10-01 | 2010-05-06 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against ionizing radiation using selective cyclin-dependent kinase 4/6 inhibitors |
CA2738925A1 (en) * | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
WO2010080452A2 (en) | 2008-12-18 | 2010-07-15 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS AND METHODS OF USE THEREOF |
EP3406260B1 (de) | 2009-05-13 | 2020-09-23 | The University of North Carolina at Chapel Hill | Cyclinabhängige kinasehemmer und verfahren zur verwendung |
ES2726766T3 (es) | 2009-08-07 | 2019-10-09 | Univ Kyoto | Método para el desarrollo eficiente de células madre pluripotentes inducidas |
SI2603600T1 (sl) | 2010-08-13 | 2019-04-30 | Aileron Therapeutics, Inc. | Peptidomimetični makrocikli |
WO2012037283A2 (en) * | 2010-09-14 | 2012-03-22 | Mount Sinai School Of Medicine | Admimistration of sns neuroprotective agents to promote hematopoietic regeration |
CN103501789A (zh) | 2010-11-17 | 2014-01-08 | 北卡罗来纳大学查珀尔希尔分校 | 通过抑制增殖性激酶cdk4和cdk6保护肾组织免于局部缺血 |
US20140088017A1 (en) | 2011-05-23 | 2014-03-27 | Yeda Research And Development Co., Ltd. | Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same |
JP2014525399A (ja) | 2011-08-09 | 2014-09-29 | ベス・イスラエル・ディーコネス・メディカル・センター,インコーポレイテッド | Dna損傷を処置する方法 |
WO2013059525A1 (en) | 2011-10-18 | 2013-04-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocyles |
CN108912211A (zh) | 2012-02-15 | 2018-11-30 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
DK2895608T3 (en) | 2012-09-12 | 2019-01-21 | Quark Pharmaceuticals Inc | DOUBLE-STRENGTHED OIGONUCLEOTIDE MOLECULES FOR P53 AND PROCEDURES FOR USING IT |
EP2914256B1 (de) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituierte aminosäuren und verfahren zur herstellung und verwendung davon |
RS59790B1 (sr) | 2013-03-15 | 2020-02-28 | G1 Therapeutics Inc | Privremena zaštita normalnih ćelija tokom hemoterapije |
JP6435315B2 (ja) | 2013-03-15 | 2018-12-05 | ジー1、セラピューティクス、インコーポレイテッドG1 Therapeutics, Inc. | 高活性抗新生物薬及び抗増殖剤 |
US10314826B2 (en) | 2014-02-07 | 2019-06-11 | University Of Maryland, Baltimore | Methods of treatment of ischemia-induced angiogenesis and arteriogenesis |
US20150297606A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation |
BR112016028009A2 (pt) | 2014-05-29 | 2018-02-20 | Quark Pharmaceuticals Inc | métodos e composições para prevenção de lesão de isquemia-reperfusão em órgãos |
WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
EP3191098A4 (de) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Kombinationen und dosierschemen zur behandlung von rb-positiven tumoren |
EP3197478A4 (de) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetische makrozyklen und verwendungen davon |
BR112017005736A2 (pt) | 2014-09-24 | 2017-12-12 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e formulações dos mesmos |
US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
US20190015393A1 (en) * | 2016-01-18 | 2019-01-17 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | The use of a temporary inhibitor of p53 for preventing or reducing cancer relapse |
EP3535396A1 (de) | 2016-11-01 | 2019-09-11 | Novartis AG | Verfahren und zusammensetzungen zur verbesserung der genbearbeitung |
US11091522B2 (en) | 2018-07-23 | 2021-08-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
WO2020206046A1 (en) | 2019-04-01 | 2020-10-08 | The Broad Institute, Inc. | Methods and compositions for cell therapy |
US20220251054A1 (en) * | 2019-06-03 | 2022-08-11 | The Regents Of The University Of California | Analogues and Methods of Treating Rett Syndrome |
JP7429035B2 (ja) | 2019-08-01 | 2024-02-07 | 東京都公立大学法人 | 機能不全ミトコンドリアを消去するための複合体、および細胞老化を抑制するための複合体 |
US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
WO2024052434A1 (en) | 2022-09-06 | 2024-03-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Engineering sox/oct heterodimerization to induce high-grade developmental reset |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2463774A1 (fr) * | 1979-08-21 | 1981-02-27 | Yamanouchi Pharma Co Ltd | Derives du 2-phenylimidazo(2,1-b)benzothiazole |
US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
CA2028756A1 (en) | 1989-11-24 | 1991-05-25 | Alfons H. M. Raeymaekers | Immunostimulating 6-aryl-5,6-dihydro-imidazo[2,1-b]thiazole derivatives |
US6372249B1 (en) * | 1991-12-16 | 2002-04-16 | Baylor College Of Medicine | Senscent cell-derived inhibitors of DNA synthesis |
JPH07291976A (ja) | 1994-04-27 | 1995-11-07 | Otsuka Pharmaceut Factory Inc | イミダゾ〔2,1−b〕チアゾール誘導体 |
CA2215197A1 (en) | 1995-03-13 | 1996-09-19 | Shigeyuki Tasaka | Imidazothiazole compound |
JP3847366B2 (ja) * | 1996-02-22 | 2006-11-22 | アンジェスMg株式会社 | アンチセンスオリゴヌクレオチドを用いた固定性分裂終了細胞増殖剤 |
AU4988997A (en) | 1996-10-23 | 1998-05-15 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
US5919808A (en) | 1996-10-23 | 1999-07-06 | Zymogenetics, Inc. | Compositions and methods for treating bone deficit conditions |
JPH1129475A (ja) | 1997-07-07 | 1999-02-02 | Sumitomo Pharmaceut Co Ltd | Stat6活性化阻害剤 |
JPH11103640A (ja) | 1997-09-29 | 1999-04-20 | Mitsubishi Agricult Mach Co Ltd | ノッタの結節装置 |
JPH11106340A (ja) | 1997-10-02 | 1999-04-20 | Sumitomo Pharmaceut Co Ltd | Stat6活性化阻害剤 |
NZ513487A (en) * | 1999-01-29 | 2003-02-28 | Univ Illinois | The use of a P53 inhibitor for the treatment of cancer, hyperthermia, hypoxia, a burn, trauma to the central nervous system, a seizure, acute inflammation, tissue ageing, preservation of organs for transplant and preparation of a host for bone marrow transplant |
-
2000
- 2000-01-28 NZ NZ513487A patent/NZ513487A/xx unknown
- 2000-01-28 US US09/493,527 patent/US6593353B1/en not_active Expired - Lifetime
- 2000-01-28 DE DE60037394T patent/DE60037394T2/de not_active Expired - Lifetime
- 2000-01-28 AT AT00914455T patent/ATE380548T1/de not_active IP Right Cessation
- 2000-01-28 CA CA002360671A patent/CA2360671A1/en not_active Abandoned
- 2000-01-28 IL IL14429400A patent/IL144294A0/xx unknown
- 2000-01-28 EP EP00914455A patent/EP1143943B1/de not_active Revoked
- 2000-01-28 WO PCT/US2000/002104 patent/WO2000044364A2/en active Application Filing
- 2000-01-28 JP JP2000595668A patent/JP2002535357A/ja active Pending
- 2000-01-28 AU AU35842/00A patent/AU3584200A/en not_active Abandoned
-
2001
- 2001-06-13 US US09/880,417 patent/US7012087B2/en not_active Expired - Lifetime
- 2001-07-12 IL IL144294A patent/IL144294A/en not_active IP Right Cessation
- 2001-07-16 ZA ZA200105823A patent/ZA200105823B/en unknown
- 2001-09-06 US US09/947,757 patent/US20020019425A1/en not_active Abandoned
-
2003
- 2003-01-24 US US10/350,560 patent/US6982277B2/en not_active Expired - Lifetime
- 2003-01-28 US US10/352,597 patent/US7008956B2/en not_active Expired - Lifetime
-
2005
- 2005-05-24 US US11/136,231 patent/US20050222224A1/en not_active Abandoned
-
2008
- 2008-01-30 US US12/022,317 patent/US20080161426A1/en not_active Abandoned
- 2008-12-04 IL IL195723A patent/IL195723A/en not_active IP Right Cessation
-
2010
- 2010-08-23 JP JP2010185868A patent/JP2010265321A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60037394T2 (de) | 2009-01-02 |
ATE380548T1 (de) | 2007-12-15 |
ZA200105823B (en) | 2002-05-07 |
US6593353B1 (en) | 2003-07-15 |
US7008956B2 (en) | 2006-03-07 |
US20030176318A1 (en) | 2003-09-18 |
WO2000044364A3 (en) | 2001-08-23 |
US20050222224A1 (en) | 2005-10-06 |
IL144294A (en) | 2010-04-15 |
IL144294A0 (en) | 2002-05-23 |
US20080161426A1 (en) | 2008-07-03 |
JP2010265321A (ja) | 2010-11-25 |
US20030144331A1 (en) | 2003-07-31 |
US7012087B2 (en) | 2006-03-14 |
US20020006941A1 (en) | 2002-01-17 |
NZ513487A (en) | 2003-02-28 |
EP1143943B1 (de) | 2007-12-12 |
WO2000044364A2 (en) | 2000-08-03 |
JP2002535357A (ja) | 2002-10-22 |
EP1143943A3 (de) | 2002-09-11 |
AU3584200A (en) | 2000-08-18 |
US6982277B2 (en) | 2006-01-03 |
EP1143943A2 (de) | 2001-10-17 |
US20020019425A1 (en) | 2002-02-14 |
IL195723A (en) | 2010-12-30 |
CA2360671A1 (en) | 2000-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60037394D1 (de) | VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE | |
ATE527022T1 (de) | Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie | |
NO20014560L (no) | Quinasoliner og terapautisk anvendelse derav | |
DE69826695D1 (de) | Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen | |
DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
DE60039415D1 (de) | Reovirus zur behandlung von zellulären proliferativen erkrankungen | |
DE60032795D1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
ATE422358T1 (de) | Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen | |
ATE308997T1 (de) | Mittel zur behandlung von erkrankungen der speiseröhre | |
ATE472325T1 (de) | Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen | |
MY138059A (en) | Use of ikb-kinase inhibitors in pain therapy | |
DE60027290D1 (de) | Skleraprothese zur behandlung der weitsichtigkeit und anderer augenkrankheiten | |
MY138883A (en) | Use of asiatic acid for treatment of cencer | |
DE60036826D1 (de) | Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs | |
ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
DE50114605D1 (de) | No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
ATE357912T1 (de) | Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten | |
DE60018200D1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
ATA901396A (de) | Verwendung von melatonin zur behandlung von an medikamentensucht leidenden patienten | |
DE69924284D1 (de) | Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten | |
DE69910425D1 (de) | Neue therapeutische verwendung von nicergoline | |
MXPA02004699A (es) | Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco. | |
DE69806062T2 (de) | Kombinationstherapie zur behandlung von aids | |
DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |